Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Corticosteroids may help manage cytokine release syndrome during teplizumab therapy
Última actualización 21 de agosto de 2026
Key finding
Maximum stimulated C-peptide decreases from about 2 to about 1.3.
This study evaluated the use of glucocorticoids to manage cytokine release syndrome during teplizumab therapy for new-onset type 1 diabetes, finding a low incidence of cytokine release syndrome.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the use of glucocorticoids to manage cytokine release syndrome during teplizumab therapy for new-onset type 1 diabetes, finding a low incidence of cytokine release syndrome.
Clinical relevance
Understanding the safety and efficacy of teplizumab in managing new-onset type 1 diabetes is crucial for clinicians. The low incidence of cytokine release syndrome suggests that teplizumab may be a viable treatment option, potentially improving patient outcomes while minimizing adverse effects.
Keep in mind
Effectiveness of teplizumab remains unclear due to lack of definitive evidence. Limited sample size may affect generalizability of findings. Variability in HbA1c levels complicates interpretation of glycemic control.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Aye K, Srinath S, Christine T, Zoe Q, Stephen EG. Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes. Diabetes Care. 2026;49(3). doi:10.2337/dc25-2494
Efectos Principales
Maximum stimulated C-peptide decreased from about 2 to about 1.3 pmol/L.
HbA1c levels were 6.3% at 6 months, 7.3% at 9 months, and 6.4% at 15 months.
Insulin requirements reduced to 0.08 units/kg/day by 17 months.
Cytokine release syndrome occurred in 5.8% of individuals treated with teplizumab.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Teplizumab and C-peptide, Cytokine release syndrome, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Teplizumab
Primary outcomes
- C-peptide
- Cytokine release syndrome
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
4
Evidence pairs
425
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
HbA1c Reduction
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Cytokine release syndrome
Teplizumab → Cytokine release syndrome
Teplizumab → Cytokine release syndrome
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerReduced insulin requirements after surgery
Teplizumab → Reduced insulin requirements after surgery
Teplizumab → Reduced insulin requirements after surgery
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- C-peptide levels decreased by 0.7 pmol/L.
- Insulin dose reduced by 0.27 units/kg/day.
- Cytokine release syndrome incidence was 5.8%.
A quién se aplica
- Individuals with new-onset type 1 diabetes.
- Patients receiving teplizumab therapy.
Tener en Cuenta
- Findings may not apply to all populations with type 1 diabetes.
- Long-term effects of teplizumab therapy are still unknown.
- Further studies are needed to confirm these results and assess broader applicability.
Entre Líneas
- Effectiveness of teplizumab remains unclear due to lack of definitive evidence.
- Limited sample size may affect generalizability of findings.
- Variability in HbA1c levels complicates interpretation of glycemic control.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Teplizumab improve c-peptide?
Limited Evidence
Current evidence does not show a clear benefit of Teplizumab for C-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Teplizumab improve cytokine release syndrome?
Limited Evidence
Current evidence does not show a clear benefit of Teplizumab for Cytokine release syndrome.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Cytokine release syndrome
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Teplizumab improve HbA1c?
Limited Evidence
Current evidence does not show a clear benefit of Teplizumab for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Teplizumab improve reduced insulin requirements after surgery?
Limited Evidence
Current evidence does not show a clear benefit of Teplizumab for Reduced insulin requirements after surgery.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Reduced insulin requirements after surgery
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
HRS-7535 improves glycemic control in adults with type 2 diabetesHigh-protein diet shows little effect on glycemic control in diabetesQCC Model Enhances Diabetes ManagementAdding medications improves blood sugar control in diabetes patients.Bariatric surgery improves glucose homeostasis in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.